Similarly to breast cancer data, in our study, PDAC with nuclear labeling had an increased mean OS compared to tumors with cytoplasmic and nuclear labeling (29.37 vs. 17.93 months), although without significant OS differences based on the staining pattern or overall Gal8 immunohistochemical score. This evidence concerns the gene LGALS8 and breast carcinoma.